Introduction
Energizing the drive to discover the molecular basis of malignant disease has been the conviction that understanding its molecular basis will lead to effective and specific therapeutic agents. The antisense approach targets a nucleotide sequence by the use of an oligonucleotide of complementary sequence. There are two theoretical advantages to targeting the gene's messenger RNA rather than targeting the gene's protein product. One is that there are fewer messenger molecules than protein product molecules. A second is that the structure of the mutation dictates the structure of an agent that can specifically bind it, i.e., the complementary nucleotide sequence.
Chronic myeloid leukemia is a good model for examining the promise of antisense therapy. The primary lesion in most cases, a reciprocal translocation between the ends of the long arms of chromosomes 9 and 22, is well characterized (1) . The result is the formation of a hybrid gene on the translocated chromosome 22, bcr-abl. This hybrid gene consists of a 5'-portion from the bcr gene on chromosome 22 , and a 3'-portion from the abl gene translocated from chromosome 9. The junction of bcr and abl thus constitutes a sequence unique to the leukemic cell population.
An antisense agent that could prevent the multiplication of cells with the hybrid sequence, but spare cells without this sequence, would have the specificity desired in a chemotherapeutic agent.
The antisense approach can be investigated either by gene transfer with the consequent production of an antisense RNA or by the administration of oligonucleotides. The latter approach has been the one generally adopted because it is simpler and permits convenient testing of a large variety of agents. Oligonucleotides of DNA, rather than of RNA, are generally used because of the former's greater stability in biological fluids. Early reports that bcr-abl antisense oligonucleotides caused sequence-specific inhibition of the growth of cytomegalovirus (CML) cell lines (2) or of colonies from CML marrow progenitors (3) aroused great interest.
We found that an antisense phosphodiester oligonucleotide directed to the bcr-abl junction had no antiproliferative effect on CML cell lines (4). We suspected that it was promptly degraded by nucleases, either-in the serum or within the cell. We also tested phosphorothioates, i.e., oligomers in which an oxygen in the naturally occurring phosphodiester linkage is replaced by sulphur to make the linkage relatively nucleaseresistant. This antisense agent was inhibitory, but the effect was not sequence-specific.
The activity principally responsible for the intracellular degradation of oligonucleotides is a 3' -exonuclease (5) . Therefore, we first tried protecting phosphodiester oligonucleotides by capping the ends. We replaced the 5'-hydroxyl group with a dimethoxytrityl group, and the 3'-hydroxyl group with a 3'-amino, 2-hydroxypropyl group. These agents did have a sequencespecific effect (4, 6) , confirming the idea that the unmodified phosphodiesters were ineffective because of exonuclease degradation. However, the inhibitory effect on proliferation was only modest. Increasing oligonucleotide concentration reduced cell concentration in a sequence-nonspecific manner.
Other investigators have also had mixed results. Some have found sequence nonspecificity (7) (8) (9) or at least nonspecificity for the specific breakpoint (10,1 1). Many studies used phosphorothioates that can have nonspecific effects. Some investigators claim the mechanism is other than an antisense one, i.e., a sequence-dependent mechanism unrelated to the bcr-abl sequence (12, 13) . Others have found no effect on the bcr-abl protein level (14) or direct inhibition of the bcr-abl-associated protein-tyrosine kinase activity (15, 16) . Problems encountered with antisense inhibition of bcr-abl have been reviewed (17) .
We reasoned that, since capped phosphodiesters had shown some promise (4), an ideal antisense agent might have phosphodiester linkages but lack ends, i.e., be a circular phosphodiester. Such a structure confers two advantages. The first is complete resistance to exonuclease activity, and the second is that such circles have the potential to bind much more tightly than linear structures because the cyclic structure limits conformational freedom (18, 19 and Tris-borate-EDTA buffer (24) . The DNA was isolated from the gels by excision, followed by elution and dialysis, and was quantitated by absorbance at 260 nm using extinction coefficients that were calculated by the nearest neighbor method (25) . Linear 5'-phosphorylated circle precursors were synthesized and then hybridized with short complementary DNA templates (Fig. 1 ). These precircle complexes bring the reactive 3' -hydroxyl and 5'-phosphate ends adjacent to one another, and these ends are ligated using aqueous BrCN/imidazole/Ni2+ (26) (27) (28) . In all cases in this study, the precircle ends were joined at the center position of a Watson-Crick binding domain. We have found that this approach gives higher yields than does ligation within the Hoogsteen domain, although the products are identical. Isolation of the circular product (the principal new product from the reaction) was carried out by gel electrophoresis. The circular products typically migrate on a gel at -0.9 times the rate of their linear precursors. Circularity was confirmed by resistance to 3'-exonuclease cleavage and by the decrease in electrophoretic mobility upon endonuclease cleavage characteristic of conversion of a circular to a linear structure. An alternative strategy for synthesizing circular oligonucleotides that provides a higher yield, involving one-step circularization from two halflength oligomers (29) , was used for some preparations. Staining of oligonucleotides in gels was done with Stains-All (Sigma, St. Louis, MO).
Immunoblotting BV173 cells (3 X 
Results
There are two types of hybrid message resulting from the two common types of translocation breakpoints. Each type of junction involves exon We chose the long polypurine stretches closest to the b3a2 junction on either side, namely, 385 nucleotides 5' to the junction in the bcr gene and 1735 nucleotides 3' to the junction in the abl gene (Fig. 1) . The oligomers were added to the culture only on the day the culture was initiated. Although the 36-nucleotide abl-directed circle was inactive, the 34-nucleotide bcr-directed circle had activity. At 13 ,uM, the bcr circle reduced the saturating cell number by 68% (note the log scale) (Fig. 2) . The controls, including both an uncapped 12-nucleotide linear control containing just the Watson-Crick bonding region and a 34-nucleotide nonsense circle, had no effect.
The effects of the same agents at a variety of concentrations on day 5 are shown in Figure 3 . The antisense circles had an antiproliferative ef- Figure 5 . At 16 ,uM, the cells arrested at a density 66% below that of the untreated control. At 32 ,M, cells arrested at nearly 90% below the untreated control. The IC50 was about 8 ,uM. Even at this concentration, the control sequences had little effect.
The effects of circular b2a2 antisense at various concentrations are shown in Figure 6 . Rather than day 5, as in the case of K(562 cells, we chose day 7 because of the slower growth of the BV173 cell line. The antisense circle inhibits growth markedly, even at 3.5 ,uM. The control sequences (circular nonsense and short and long linear antisense) had virtually no effect. The circularization is clearly important because the same sequence prior to circularization (long linear sequence) had little effect.
Stability of Circular Oligonucleotides
To directly determine the stability of circles, we incubated circular and uncapped linear oligomers of the same length in 10% FBS at 37°C for 0-72 hr and analyzed the products on a sequencing gel. of breakdown products (Fig. 7) . No such progressive accumulation of breakdown products was seen in the case of the circular agents, indicating their greater stability.
Effect on bcr-abl Protein To demonstrate that a given oligonucleotide is acting via an antisense mechanism, the most conclusive evidence is the demonstration that the protein product of the target gene has been reduced in amount. To determine whether our antisense circle reduced the amount of bcr-abl protein in treated cells, we used immunoblotting. BV173 cells were cultured with antisense or nonsense circle for 1, 2, or 3 days. The harvested cells were lysed and the lysate electrophoresed. The electropherogram was exposed to a specific anti-bcr-abl monoclonal antibody. The signal was captured as an image by chemiluminescence and quantitated by densitometry (Fig. 8) . This methodology showed that antisense circles specifically reduced bcr-abl protein content (Fig. 9) . At 24 hr, antisense circle-treated cells (6) .
Circular oligonucleotides have a number of advantages over linear oligonucleotides as modulators of gene expression. These advantages include marked nuclease resistance, binding affinity, and sequence selectivity. The chemical basis for these properties has been described in detail (31) . Circles also have some disadvantages, including the requirement for manual preparation, difficulty in closing the circle for certain oligonucleotide lengths, and the lack of a convenient method of labeling. The last-named disadvantage accounts for our lack of information on the kinetics of cellular uptake. Perhaps the most serious limitation is the limitation of target sequences to polypurine sequences. In the case of CML, this limitation prevented choosing the bcr3/abl2 junction as a target. Although an alternative target resulted in an equivalent IC50, a penalty might be the unintended targeting of some other mRNA that might share this sequence.
Nearly as important as the circular structure of these agents may be their phosphodiester structure. The substitution of other types of internucleotide linkages appears to contribute to the lack of sequence selectivity evident in the antisense oligonucleotide literature.
Circular oligonucleotides can be made, not only from DNA but also from RNA (28) . An advantage of RNA circles over DNA circles for use as antisense molecules is their ability to bind a nucleotide in a target RNA molecule, not only by a Watson-Crick bond but also simultaneously by a Hoogsteen bond, thus forming a triplex structure (32) . Because ribonuclease is so ubiquitous, the RNAse-resistant 2'-O-methyl derivative of RNA, which has similar DNA-binding properties, may be preferable to RNA itself (32) .
This report demonstrates that one of the main obstacles to antisense therapeutics, the sensitivity of oligonucleotides to nucleases, can be addressed, not by modifying the phosphodiester structure but by circularization while preserving the phosphodiester structure. Although antisense therapy for leukemias may still face obstacles, chemical innovation is far from exhausted.
